Last reviewed · How we verify
Enoksetin (ENOXACIN)
Enoxacin, also known as Enoxacin, is a small molecule antibiotic in the enoxacin class that targets the TARBP2 subunit of the RISC-loading complex. It was originally developed and is currently owned by a pharmaceutical company. Enoxacin is FDA-approved for various indications related to gonorrhea and urinary tract infections. The drug has a bioavailability of 87% and a half-life of 5.1 hours. Enoxacin is off-patent, meaning it is no longer protected by patents.
At a glance
| Generic name | ENOXACIN |
|---|---|
| Drug class | enoxacin |
| Target | RISC-loading complex subunit TARBP2 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
- Acute gonococcal cervicitis
- Acute gonococcal urethritis
- Gonorrhea
- Gonorrhea of pharynx
- Gonorrhea of rectum
- Urinary tract infectious disease
Common side effects
Drug interactions
- famotidine
- magnesium hydroxide
- magnesium oxide
- nizatidine
- ranitidine
- sodium bicarbonate
- sucralfate
- theophylline
Key clinical trials
- Enoxacin for Amyotrophic Lateral Sclerosis (ALS) (PHASE1,PHASE2)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Sensitivity of Antibiotics for Urinary Tract Infections Patients Attending Family Physicians
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoksetin CI brief — competitive landscape report
- Enoksetin updates RSS · CI watch RSS